Thinly traded Sona Nanotech (OTCQB:SNANF +8.2%) is in the green, albeit on turnover of only 10K shares, on the heels of its announcement of performance data on its rapid COVID-19 antigen test.
Based on a bank of 99 patient samples previously analyzed by real-time polymerase chain reaction (RT-PCR) molecular tests, Sona’s assay showed 84.6% sensitivity (detecting true positives) and 90.0% specificity (detecting true negatives).
Applications are in process in Canada and the U.S. seeking emergency use authorizations during the pandemic.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.